Volume 9, Issue 1 (Vol.9 No.1 Apr 2020)
rbmb.net 2020, 9(1): 1-7 |
Back to browse issues page
Mona Djalali 
, Mahmoud Djalali , Mina Abdolahi , Hamed Mohammadi , Hajar Heidari , Shayesteh Hosseini , Majid Sadeghizadeh *
, Mahmoud Djalali , Mina Abdolahi , Hamed Mohammadi , Hajar Heidari , Shayesteh Hosseini , Majid Sadeghizadeh *
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract: (3704 Views)
Background: This study was designed to investigate the effect of nano-curcumin supplementation on pentraxin 3 (PTX3) gene expression and serum level in migraine patients.
Methods: The present study, performed as a clinical trial, included 38 episodic migraine patients in two groups that received either nano-curcumin or placebo over a two-month period. At the start and the end of the study, PTX3 gene expression and serum levels were measured.
Results: After two months of treatment, PTX3 gene expression and serum levels were both significantly less in the nano-curcumin than in the placebo group (P= 0.01 and P< 0.001, respectively). No significant gene expression differences were found between the two groups.
Conclusions: Curcumin may have a potential inhibitory effect on PTX3 gene expression and serum levels in migraine disease and can be considered as an efficient therapy in migraine management.
Methods: The present study, performed as a clinical trial, included 38 episodic migraine patients in two groups that received either nano-curcumin or placebo over a two-month period. At the start and the end of the study, PTX3 gene expression and serum levels were measured.
Results: After two months of treatment, PTX3 gene expression and serum levels were both significantly less in the nano-curcumin than in the placebo group (P= 0.01 and P< 0.001, respectively). No significant gene expression differences were found between the two groups.
Conclusions: Curcumin may have a potential inhibitory effect on PTX3 gene expression and serum levels in migraine disease and can be considered as an efficient therapy in migraine management.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2019/11/1 | Accepted: 2020/02/18 | Published: 2020/05/19
Received: 2019/11/1 | Accepted: 2020/02/18 | Published: 2020/05/19
References
1. 1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed M, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-9. [DOI:10.1212/01.wnl.0000252808.97649.21]
2. Steiner, T. J., Stovner, L. J., & Birbeck, G. L. (2013). Migraine: the seventh disabler. The journal of headache and pain, 14(1), 1. [DOI:10.1186/1129-2377-14-1]
3. Mulder EJ, Van Baal C, Gaist D, Kallela M, Kaprio J, Svensson DA, et al. Genetic and environmental influences on migraine: a twin study across six countries. Twin Res. 2003;6(5):422-31. 4. Malhotra R. Understanding migraine: Potential role of neurogenic inflammation. Ann Indian Acad Neurol. 2016;19(2):175-82. [DOI:10.4103/0972-2327.182302]
4. Honarvar NM, Saedisomeolia A, Abdolahi M, Shayeganrad A, Sangsari GT, Rad BH, et al. Molecular anti-inflammatory mechanisms of retinoids and carotenoids in Alzheimer's disease: A review of current evidence. J Mol Neurosci. 2017;61(3):289-304. [DOI:10.1007/s12031-016-0857-x]
5. Soveyd N, Abdolahi M, Bitarafan S, Tafakhori A, Sarraf P, Togha M, et al. Molecular mechanisms of omega-3 fatty acids in the migraine headache. Iran J Neurol. 2017;16(4):210-217.
6. Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009;205(1):15-22. [DOI:10.1016/j.atherosclerosis.2008.10.016]
7. Longoni M, Ferrarese C. Inflammation and excitotoxicity: role in migraine pathogenesis. Neurol Sci. 2006;27 suppl 2:s107-10. [DOI:10.1007/s10072-006-0582-2]
8. Lippi G, Mattiuzzi C, Cervellin G. C-reactive protein and migraine. Facts or speculations?. Clin Chem Lab Med. 2014;52(9):1265-72. [DOI:10.1515/cclm-2014-0011]
9. Ryu WS, Kim CK, Kim BJ, Kim C, Lee SH, Yoon BW. Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis. 2012;220(2):581-6. [DOI:10.1016/j.atherosclerosis.2011.11.036]
10. Ceylan M, Bayraktutan OF, Becel S, Atis Ö, Yalcin A, Kotan D. Serum levels of pentraxin-3 and other inflammatory biomarkers in migraine: association with migraine characteristics. Cephalalgia. 2016;36(6):518-25. [DOI:10.1177/0333102415598757]
11. Wärnberg J, Gomez‐Martinez S, Romeo J, Díaz LE, Marcos A. Nutrition, inflammation, and cognitive function. Ann N Y Acad Sci. 2009;1153:164-75. [DOI:10.1111/j.1749-6632.2008.03985.x]
12. Shehzad A, Wahid F, Lee YS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim). 2010;343(9):489-99. [DOI:10.1002/ardp.200900319]
13. Shishodia S. Molecular mechanisms of curcumin action: gene expression. Biofactors. 2013;39(1):37-55. [DOI:10.1002/biof.1041]
14. Mottaghi A, Salehi E, Keshvarz A, Sezavar H, Saboor-Yaraghi A-A. The influence of vitamin A supplementation on Foxp3 and TGF-β gene expression in atherosclerotic patients. J Nutrigenet Nutrigenomics. 2012;5(6):314-26. [DOI:10.1159/000341916]
15. Tietjen GE. Migraine as a systemic vasculopathy. Cephalalgia. 2009;29(9):989-96. [DOI:10.1111/j.1468-2982.2009.01937.x]
16. Gerring ZF, Powell JE, Montgomery GW, Nyholt DR. Genome-wide analysis of blood gene expression in migraine implicates immune-inflammatory pathways. Cephalalgia. 2018;38(2):292-303. [DOI:10.1177/0333102416686769]
17. Levy D. Migraine pain and nociceptor activation-where do we stand?. Headache.2010;50(5):909-16. [DOI:10.1111/j.1526-4610.2010.01670.x]
18. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365-91. [DOI:10.1146/annurev-physiol-030212-183717]
19. Liu R, Ma M, Cui M, Dong Z, Wang X, Zhang W, et al. Effects of tumor necrosis factor-β (TNF-β) 252A> G polymorphism on the development of migraine: a meta-analysis. PLoS One. 2014;9(6):e100189. [DOI:10.1371/journal.pone.0100189]
20. Casula M, Montecucco F, Bonaventura A, Liberale L, Vecchié A, Dallegri F, et al. Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017;99:1-12. [DOI:10.1016/j.vph.2017.10.003]
21. Bisht K, Wagner KH, Bulmer AC. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto-and DNA-protective dietary compounds. Toxicology. 2010;278(1):88-100. [DOI:10.1016/j.tox.2009.11.008]
22. Abdolahi M, Tafakhori A, Togha M, Okhovat AA, Siassi F, Eshraghian MR, et al. The synergistic effects of ω-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-α gene expression and serum level in migraine patients. Immunogenetics. 2017;69(6):371-378. [DOI:10.1007/s00251-017-0992-8]
23. Singh AK, Vinayak M. Curcumin attenuates CFA induced thermal hyperalgesia by modulation of antioxidant enzymes and down regulation of TNF-α, IL-1β and IL-6. Neurochem Res. 2015;40(3):463-72. [DOI:10.1007/s11064-014-1489-6]
24. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol. 2003;33(10):2886-93. [DOI:10.1002/eji.200324390]
25. Fu Y, Gao R, Cao Y, Guo M, Wei Z, Zhou E, et al. Curcumin attenuates inflammatory responses by suppressing TLR4-mediated NF-κB signaling pathway in lipopolysaccharide-induced mastitis in mice. Int Immunopharmacol. 2014;20(1):54-8. [DOI:10.1016/j.intimp.2014.01.024]
26. Zhu HT, Bian C, Yuan JC, Chu WH, Xiang X, Chen F, et al. Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappaB signaling pathway in experimental traumatic brain injury. J Neuroinflammation. 2014;11:59. [DOI:10.1186/1742-2094-11-59]
27. Yu S, Wang X, He X, Wang Y, Gao S, Ren L, et al. Curcumin exerts anti-inflammatory and antioxidative properties in 1-methyl-4-phenylpyridinium ion (MPP (+))-stimulated mesencephalic astrocytes by interference with TLR4 and downstream signaling pathway. Cell Stress Chaperones. 2016;21(4):697-705. [DOI:10.1007/s12192-016-0695-3]
28. Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol Carcinog. 2006;45(5):320-32. [DOI:10.1002/mc.20170]
29. Zhang J, Koussih L, Shan L, Halayko AJ, Chen BK, Gounni AS. TNF up-regulates Pentraxin3 expression in human airway smooth muscle cells via JNK and ERK1/2 MAPK pathways. Allergy Asthma Clin Immunol. 2015;11:37. [DOI:10.1186/s13223-015-0104-y]
30. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. 2012;69(1):65-70. [DOI:10.1007/s00280-011-1673-1]
31. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5. [DOI:10.1248/bpb.34.660]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |